Miller Fisher syndrome with presynaptic neuromuscular transmission disorder
Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ehler, Edvard [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR - Song, Chun-hui ELSEVIER, 2023, Burlington, Mass |
|---|---|
| Übergeordnetes Werk: |
volume:21 ; year:2014 ; number:11 ; pages:2025-2027 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jocn.2014.05.050 |
|---|
| Katalog-ID: |
ELV028276876 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV028276876 | ||
| 003 | DE-627 | ||
| 005 | 20230623193038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jocn.2014.05.050 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014015000030.pica |
| 035 | |a (DE-627)ELV028276876 | ||
| 035 | |a (ELSEVIER)S0967-5868(14)00495-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.00 |2 bkl | ||
| 100 | 1 | |a Ehler, Edvard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| 264 | 1 | |c 2014 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. | ||
| 650 | 7 | |a Fisher syndrome |2 Elsevier | |
| 650 | 7 | |a Ophthalmoparesis |2 Elsevier | |
| 650 | 7 | |a Neuromuscular transmission disorder |2 Elsevier | |
| 650 | 7 | |a Single-fiber electromyography |2 Elsevier | |
| 700 | 1 | |a Latta, Jan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Song, Chun-hui ELSEVIER |t New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |d 2023 |g Burlington, Mass |w (DE-627)ELV009125612 |
| 773 | 1 | 8 | |g volume:21 |g year:2014 |g number:11 |g pages:2025-2027 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jocn.2014.05.050 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.00 |j Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 21 |j 2014 |e 11 |h 2025-2027 |g 3 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
e e ee |
|---|---|
| matchkey_str |
ehleredvardlattajan:2014----:ilrihrydoeihrsnpinuouclrr |
| hierarchy_sort_str |
2014 |
| bklnumber |
35.00 |
| publishDate |
2014 |
| allfields |
10.1016/j.jocn.2014.05.050 doi GBVA2014015000030.pica (DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.00 bkl Ehler, Edvard verfasserin aut Miller Fisher syndrome with presynaptic neuromuscular transmission disorder 2014 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier Latta, Jan oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:21 year:2014 number:11 pages:2025-2027 extent:3 https://doi.org/10.1016/j.jocn.2014.05.050 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 21 2014 11 2025-2027 3 045F 610 |
| spelling |
10.1016/j.jocn.2014.05.050 doi GBVA2014015000030.pica (DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.00 bkl Ehler, Edvard verfasserin aut Miller Fisher syndrome with presynaptic neuromuscular transmission disorder 2014 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier Latta, Jan oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:21 year:2014 number:11 pages:2025-2027 extent:3 https://doi.org/10.1016/j.jocn.2014.05.050 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 21 2014 11 2025-2027 3 045F 610 |
| allfields_unstemmed |
10.1016/j.jocn.2014.05.050 doi GBVA2014015000030.pica (DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.00 bkl Ehler, Edvard verfasserin aut Miller Fisher syndrome with presynaptic neuromuscular transmission disorder 2014 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier Latta, Jan oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:21 year:2014 number:11 pages:2025-2027 extent:3 https://doi.org/10.1016/j.jocn.2014.05.050 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 21 2014 11 2025-2027 3 045F 610 |
| allfieldsGer |
10.1016/j.jocn.2014.05.050 doi GBVA2014015000030.pica (DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.00 bkl Ehler, Edvard verfasserin aut Miller Fisher syndrome with presynaptic neuromuscular transmission disorder 2014 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier Latta, Jan oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:21 year:2014 number:11 pages:2025-2027 extent:3 https://doi.org/10.1016/j.jocn.2014.05.050 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 21 2014 11 2025-2027 3 045F 610 |
| allfieldsSound |
10.1016/j.jocn.2014.05.050 doi GBVA2014015000030.pica (DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.00 bkl Ehler, Edvard verfasserin aut Miller Fisher syndrome with presynaptic neuromuscular transmission disorder 2014 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier Latta, Jan oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:21 year:2014 number:11 pages:2025-2027 extent:3 https://doi.org/10.1016/j.jocn.2014.05.050 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 21 2014 11 2025-2027 3 045F 610 |
| language |
English |
| source |
Enthalten in New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR Burlington, Mass volume:21 year:2014 number:11 pages:2025-2027 extent:3 |
| sourceStr |
Enthalten in New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR Burlington, Mass volume:21 year:2014 number:11 pages:2025-2027 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Fisher syndrome Ophthalmoparesis Neuromuscular transmission disorder Single-fiber electromyography |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| authorswithroles_txt_mv |
Ehler, Edvard @@aut@@ Latta, Jan @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009125612 |
| dewey-sort |
3610 |
| id |
ELV028276876 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028276876</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623193038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jocn.2014.05.050</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014015000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028276876</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0967-5868(14)00495-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ehler, Edvard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Miller Fisher syndrome with presynaptic neuromuscular transmission disorder</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fisher syndrome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ophthalmoparesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuromuscular transmission disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Single-fiber electromyography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latta, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Song, Chun-hui ELSEVIER</subfield><subfield code="t">New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR</subfield><subfield code="d">2023</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV009125612</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:2025-2027</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jocn.2014.05.050</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">2025-2027</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ehler, Edvard |
| spellingShingle |
Ehler, Edvard ddc 610 ddc 540 bkl 35.00 Elsevier Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| authorStr |
Ehler, Edvard |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009125612 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 35.00 bkl Miller Fisher syndrome with presynaptic neuromuscular transmission disorder Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography Elsevier |
| topic |
ddc 610 ddc 540 bkl 35.00 Elsevier Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.00 Elsevier Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography |
| topic_browse |
ddc 610 ddc 540 bkl 35.00 Elsevier Fisher syndrome Elsevier Ophthalmoparesis Elsevier Neuromuscular transmission disorder Elsevier Single-fiber electromyography |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j l jl |
| hierarchy_parent_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| hierarchy_parent_id |
ELV009125612 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009125612 |
| title |
Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| ctrlnum |
(DE-627)ELV028276876 (ELSEVIER)S0967-5868(14)00495-0 |
| title_full |
Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| author_sort |
Ehler, Edvard |
| journal |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| journalStr |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
2025 |
| author_browse |
Ehler, Edvard |
| container_volume |
21 |
| physical |
3 |
| class |
610 610 DE-600 540 VZ 35.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ehler, Edvard |
| doi_str_mv |
10.1016/j.jocn.2014.05.050 |
| dewey-full |
610 540 |
| title_sort |
miller fisher syndrome with presynaptic neuromuscular transmission disorder |
| title_auth |
Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| abstract |
Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. |
| abstractGer |
Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. |
| abstract_unstemmed |
Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
11 |
| title_short |
Miller Fisher syndrome with presynaptic neuromuscular transmission disorder |
| url |
https://doi.org/10.1016/j.jocn.2014.05.050 |
| remote_bool |
true |
| author2 |
Latta, Jan |
| author2Str |
Latta, Jan |
| ppnlink |
ELV009125612 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.jocn.2014.05.050 |
| up_date |
2024-07-06T18:23:23.747Z |
| _version_ |
1803855020684214272 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028276876</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623193038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jocn.2014.05.050</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014015000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028276876</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0967-5868(14)00495-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ehler, Edvard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Miller Fisher syndrome with presynaptic neuromuscular transmission disorder</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Miller Fisher syndrome is defined by a triad of symptoms, namely areflexia, ataxia, and ophthalmoparesis. The ophthalmoparesis is mostly severe, undulating weakness of eye movements with ptosis and increased fatigability resembling a neuromuscular transmission disorder. We present a 52-year-old man with severe Miller Fisher syndrome with a high level of anti-GQ1b antibodies and a presynaptic type of neuromuscular transmission disorder. The diagnosis was confirmed by stimulated single-fiber electromyography with the use of a concentric needle electrode and various stimulation rates.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fisher syndrome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ophthalmoparesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuromuscular transmission disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Single-fiber electromyography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latta, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Song, Chun-hui ELSEVIER</subfield><subfield code="t">New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR</subfield><subfield code="d">2023</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV009125612</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:2025-2027</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jocn.2014.05.050</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">2025-2027</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4028435 |